Carless P A, Henry D A, Moxey A J, O'connell D L, Brown T, Fergusson D A
Faculty of Health, The University of Newcastle, Discipline of Clinical Pharmacology, Level 5, Clinical Sciences Building, Newcastle Mater Hospital, Edith Street, Waratah, Newcastle, New South Wales, Australia.
Cochrane Database Syst Rev. 2006 Oct 18(4):CD001888. doi: 10.1002/14651858.CD001888.pub2.
Concerns regarding the safety of transfused blood, have prompted reconsideration of the use of allogeneic (blood from an unrelated donor) red blood cell (RBC) transfusion, and a range of techniques to minimise transfusion requirements.
To examine the evidence for the efficacy of cell salvage in reducing allogeneic blood transfusion and the evidence for any effect on clinical outcomes.
We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Current Contents and the websites of international health technology assessment agencies. The reference lists in identified trials and review articles were also searched, and study authors were contacted to identify additional studies. The searches were updated in January 2004.
Controlled parallel group trials in which adult patients, scheduled for non-urgent surgery, were randomised to cell salvage, or to a control group, who did not receive the intervention.
Two authors independently screened search results, extracted data and assessed methodological quality. The main outcomes measures were the number of patients exposed to allogeneic red cell transfusion, and the amount of blood transfused. Other outcomes measured were re-operation for bleeding, blood loss, post-operative complications (thrombosis, infection, non-fatal myocardial infarction, renal failure), mortality, and length of hospital stay (LOS).
Overall, the use of cell salvage reduced the rate of exposure to allogeneic RBC transfusion by a relative 39% (relative risk [RR] = 0.61: 95% confidence interval [CI] 0.52 to 0.71). The absolute reduction in risk (ARR) of receiving an allogeneic RBC transfusion was 23% (95% CI 16% to 30%). In orthopaedic procedures the RR of exposure to RBC transfusion was 0.42 (95% CI 0.32 to 0.54) compared to 0.77 (95% CI 0.68 to 0.87) for cardiac procedures. The use of cell salvage resulted in an average saving of 0.67 units of allogeneic RBC per patient (weighted mean difference was -0.64; 95% CI -0.89 to -0.45). Cell salvage did not appear to impact adversely on clinical outcomes.
AUTHORS' CONCLUSIONS: The results suggest cell salvage is efficacious in reducing the need for allogeneic red cell transfusion in adult elective surgery. However, the methodological quality of trials was poor. As the trials were unblinded and lacked adequate concealment of treatment allocation, transfusion practices may have been influenced by knowledge of the patients' treatment status biasing the results in favour of cell salvage.
对输血安全性的担忧促使人们重新考虑使用异体(来自非亲属供体的血液)红细胞(RBC)输血,以及一系列将输血需求降至最低的技术。
研究自体血回输在减少异体输血方面的疗效证据以及对临床结局影响的证据。
我们检索了Cochrane对照试验中央注册库、MEDLINE、EMBASE、《现刊目次》以及国际卫生技术评估机构的网站。还检索了已识别试验和综述文章中的参考文献列表,并联系研究作者以识别其他研究。检索于2004年1月更新。
针对计划进行非急诊手术的成年患者的对照平行组试验,这些患者被随机分配至自体血回输组或未接受该干预措施的对照组。
两位作者独立筛选检索结果、提取数据并评估方法学质量。主要结局指标为接受异体红细胞输血的患者数量以及输血量。测量的其他结局包括因出血进行的再次手术、失血量、术后并发症(血栓形成、感染、非致命性心肌梗死、肾衰竭)、死亡率以及住院时间(LOS)。
总体而言,使用自体血回输使异体红细胞输血的暴露率相对降低了39%(相对危险度[RR]=0.61:95%置信区间[CI]0.52至0.71)。接受异体红细胞输血的绝对风险降低率(ARR)为23%(95%CI 16%至30%)。在骨科手术中,红细胞输血暴露的RR为0.42(95%CI 0.32至0.54),而心脏手术为0.77(95%CI 0.68至0.87)。使用自体血回输使每位患者平均节省0.67单位异体红细胞(加权平均差为-0.64;95%CI -0.89至-0.45)。自体血回输似乎未对临床结局产生不利影响。
结果表明自体血回输在减少成人择期手术中异体红细胞输血需求方面是有效的。然而,试验的方法学质量较差。由于试验未设盲且缺乏对治疗分配的充分隐匿,输血实践可能受到患者治疗状态知晓情况的影响,从而使结果偏向自体血回输。